Genetic Analysis AS (XSAT:GEAN)

Sweden · Delayed Price · Currency is SEK · Price in NOK

0.685

-0.015 (-2.14%)

At close: Feb 27, 2026

-16.46% (1Y)

Market Cap	44.87M
Revenue (ttm)	19.36M
Net Income (ttm)	-10.44M
Shares Out	69.09M
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	95,779
Average Volume	45,890
Open	0.720
Previous Close	0.700
Day's Range	0.685 - 0.750
52-Week Range	0.530 - 2.600
Beta	2.30
RSI	47.50
Earnings Date	Feb 27, 2026

About Genetic Analysis AS

Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discovery, a tool to search biomarkers and validate research findings or transfer the findings to a ready-to-use routine testing platform; GA-map Sample Colle... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 2008

Employees 16

Stock Exchange Spotlight Stock Market

Ticker Symbol GEAN

Full Company Profile

Financial Performance

In 2025, Genetic Analysis AS's revenue was 21.17 million, an increase of 2.36% compared to the previous year's 20.68 million. Losses were -11.42 million, -22.71% less than in 2024.

Financial numbers in NOK Financial Statements

News

There is no news available yet.